Bolt Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Bolt Biotherapeutics's earnings have been declining at an average annual rate of -20.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 70.3% per year.
Key information
-20.2%
Earnings growth rate
46.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 70.3% |
Return on equity | -61.4% |
Net Margin | -878.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully
Mar 15Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
May 13Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Dec 01Bolt Biotherapeutics: A Promised Follow Up
Aug 26Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Aug 10We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Jul 27We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Apr 12We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth
Dec 03Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Aug 18We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely
Aug 18Revenue & Expenses BreakdownBeta
How Bolt Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 8 | -69 | 23 | 0 |
30 Sep 23 | 7 | -71 | 23 | 0 |
30 Jun 23 | 7 | -77 | 22 | 0 |
31 Mar 23 | 7 | -81 | 22 | 0 |
31 Dec 22 | 6 | -88 | 23 | 0 |
30 Sep 22 | 5 | -95 | 22 | 0 |
30 Jun 22 | 3 | -97 | 22 | 0 |
31 Mar 22 | 2 | -98 | 20 | 0 |
31 Dec 21 | 1 | -99 | 18 | 0 |
30 Sep 21 | 1 | -102 | 15 | 0 |
30 Jun 21 | 0 | -89 | 13 | 0 |
31 Mar 21 | 0 | -77 | 11 | 0 |
31 Dec 20 | 0 | -61 | 9 | 0 |
30 Sep 20 | 0 | -39 | 9 | 0 |
30 Jun 20 | 0 | -36 | 8 | 0 |
31 Mar 20 | 0 | -32 | 6 | 0 |
31 Dec 19 | 0 | -30 | 5 | 0 |
Quality Earnings: BOLT is currently unprofitable.
Growing Profit Margin: BOLT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOLT is unprofitable, and losses have increased over the past 5 years at a rate of 20.2% per year.
Accelerating Growth: Unable to compare BOLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BOLT has a negative Return on Equity (-61.38%), as it is currently unprofitable.